Synthetic Biology Company 'Sconry Biopharma' Completes Pre-A Round Financing, Focusing on Biological Fermentation and Enzyme Catalysis Technology Research, with Strategic Layout in Bio-based Materials and Health Sectors
Published: August 7, 2024, 19:41 Source: Sconry Biopharma Shanghai
In July 2024, Sconry Biopharma (Shanghai) Co., Ltd. successfully completed its Pre-A round of financing, co-invested by Mr. He Haichao, Chairman of JW Machinery and Chairman of JW Fund, along with Mr. Xie Youbang and Mr. Fang Ying, founding partners of JW Fund. This round of financing will be used forresearch and development in synthetic biology fermentation and enzyme catalysis technologies, with strategic focus on bio-based materials and the health sector.
Sconry Biopharma (Shanghai) Co., Ltd. was established in 2022, and is a product-oriented biotechnology company focused on synthetic biology. The company adheres to the philosophy of "Nature's Workmanship, Taken from Nature, Used for Nature", and focuses on green science and green value creation from the perspective of "engineering" and "industrialization," developing multiple core technologies. After years of effort by the R&D team, the company has developed product pipelines such as 1,3-propanediol, 5-aminolevulinic acid, calcium propionate, hexamidine, and NAD+, with applications in fields such as fine chemicals, biological raw materials, skincare functional ingredients, and plant/animal protection functional ingredients. It has builtan enzyme library of over 2000 catalytic chemical reactions, rapidly advancing the industrialization process of enzyme-catalyzed synthesis of glufosinate and L-serine for glufosinate synthesis.
